替米沙坦联合胺碘酮用于预防心房纤颤复发100例临床疗效观察

The Telmisartan Joint Amiodarone For The prevention of Atrial Fibrillation Recurrence 100 Clinical Observation

目的:探讨替米沙坦与小剂量胺碘酮联合应用预防心房纤颤复发的临床疗效。方法:200例阵发性房颤经口服胺碘酮转复为窦性心律的患者,随机分为胺碘酮联合替米沙坦组及胺碘酮联合美托洛尔组,随访时间为1年,比较两组治疗后3、6及12个月的窦性心律维持情况以及治疗前后的左心房内径。结果:治疗3、6、12个月后,治疗组窦性心律维持率为89.5%、84.2%、81.5%,对照组为87.0%、81.2%、78.6%,两组差异无统计学意义(P>0.05)。治疗后3个月两组患者左房前后径差异无统计学意义(P>0.05),但治疗第6个月及12个月,治疗组左房内径小于对照组(P<0.05),差异有统计学意义。结论:胺碘酮与替米沙坦联后用于预防心房纤颤复发,维持窦性心律的疗效与胺碘酮联用美托洛尔组相似,而抑制左心房重构的作用优于对照组。

Objective：To investigate the combined prevention of atrial fibrillation recurrence of the clinical efficacy of telmisartan with a small dose amiodarone.Methods：200 patients with paroxysmal atrial fibrillation cardioversion by oral amiodarone for sinus rhythm patients were randomly divided into amiodarone telmisartan and amiodarone in the metoprolol group were followed up for 1 year 3 months,6 months and 12 months,sinus rhythm maintenance as well as before and after treatment of left atrial diameter,were compared between the two groups after treatment.Results：The treatment for 3 months,6 months,12 months after the treatment group sinus rhythm maintenance rate was 89.5%,84.2%,81.5% in the control group was 87.0%,81.2%,78.6%,there was no significant difference（P0.05）.Before and after 3 months two groups of patients with left atrial diameter after treatment no significant difference（P0.05）,but treatment of the first six months and 12 months,the treatment group,left atrial diameter is less than the control group（P0.05）,there are statistically significant.Conclusion：Amiodarone with telmisartan used for the prevention of atrial fibrillation recurrence and the efficacy of maintaining sinus rhythm with amiodarone combined with metoprolol group,while inhibiting the remodeling of the left atrium superior to the control group.